Gracecast Lung Cancer Audio
ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:05:13
- More information
Informações:
Synopsis
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
